Apexigen, Inc.

Apexigen, Inc. is a clinical-stage biopharmaceutical company focused on cancer immunology and the discovery of novel antibody-based therapies for oncology indications. The company entered public markets through a de-SPAC business combination with Brookline Capital Acquisition Corp, a blank-check vehicle sponsored by Brookline Capital Markets that completed its initial public offering in 2021. An 8-K filed with the SEC on March 18, 2022 reflects corporate disclosures tied to activity surrounding that transaction. Following the merger's close, Apexigen traded on Nasdaq under the ticker APGN. Investors and analysts tracking oncology SPAC transactions can access full filing histories, sponsor profiles, and deal analytics for Apexigen and hundreds of other SPACs by signing up at SpacDesk.